Synergy Innovation Signs Overseas Supply Contract Worth 5.8 Billion KRW for COVID-19 Specimen Collection Kits

[Asia Economy Reporter Jang Hyowon] Synergy Innovation has signed a contract to supply COVID-19 specimen collection kits to the North American region through domestic distributors. The contract amount is 5.75 billion KRW, which exceeds 50% of Synergy Innovation's sales based on last year's separate financial statements.

The company evaluated that securing global trust in quality through US FDA product approval and European CE certification is the reason for the increase in overseas demand. To stably supply the volume, the company is actively responding to the increase in overseas demand by additionally expanding production facilities.

A company official stated, "As the COVID-19 pandemic phenomenon continues worldwide, demand for specimen collection kits is expected to steadily continue. We are currently negotiating details for additional sales in Asia, Africa, and Europe besides the North American region," adding, "We recently completed the expansion of production facilities, including automation equipment, and are reviewing facility expansion in preparation for additional supply contracts and increased overseas demand."

Meanwhile, Synergy Innovation possesses the largest GMP production facility in Korea, capable of producing 4 million specimen collection kits per month, and it is reported that negotiations are underway for joint sales with domestic diagnostic kit manufacturers.

This content was produced with the assistance of AI translation services.